Riskpilot← Back to searchSign inGet full accessNormedico AB
ABActiveOrg 5566617303Garphyttegränd 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20040 employees
Revenue 2024
SEK 57K
-40% vs 2023
EBITDA margin
-319.3%
-10% vs 2023
Equity ratio
2.6%
Financial strength
Net profit 2024
SEK -271K
+2% vs 2023
| Revenue | SEK 57K | -40% |
| EBITDA | SEK -182K | -10% |
| Net profit | SEK -271K | +2% |
| Total assets | SEK 4,4M | -1% |
| Equity | SEK 114K | -2% |
| Employees | 0 | — |
Legal name
Normedico AB
Org number
5566617303
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
28 april 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva import och export av medicinsk- och dentalutrustning samt dentalprodukter inom tandläkarvården samt därmed förenlig verksamhet. Äga och förvalta fastigheter och värdepapper samt därmed förenlig verksamhet.
Address
Garphyttegränd 2
Phone
+4687517777
Email
info@normedico.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 30 | 120 | 154 | 95 | 57 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −127 | −726 | −332 | −165 | −182 |
| Depreciation & amort. | −0 | −0 | −0 | −111 | −89 |
| EBIT | −127 | −726 | −332 | −276 | −271 |
| Net financials | −1 | −617 | −1 | — | — |
| Profit before tax | −128 | −1 035 | −333 | −277 | −271 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −128 | −1 035 | −333 | −277 | −271 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 488 | 4 408 | 4 671 | 4 462 | 4 432 |
| Equity | 272 | 237 | 212 | 116 | 114 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 215 | 4 171 | 4 459 | 4 346 | 4 318 |
| Total debt | 4 215 | 4 171 | 4 459 | 4 346 | 4 318 |
EBITDA margin
-319.3%
This company
15.8%
Market median
-2121% vs market
20202024
Equity ratio
2.6%
This company
38.2%
Market median
-93% vs market
20202024
Return on equity
-237.7%
This company
18.4%
Market median
-1392% vs market
20202024
Net profit margin
-475.4%
This company
8.1%
Market median
-5969% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
37.88×
This company
0.62×
Market median
-6010% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Normedico AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Faramarz Norouzi | Deputy Board Member | 0 companies |
| Farshid Norouzi | Board of Directors | 0 companies |